Beacon Makes £96m Debut With Gene Therapy Pipeline For Unmet Retinal Needs
Backed By Syncona
The UK firm’s substantial series A raise will help it advance a pipeline of gene therapy candidates for both rare and common retinal conditions, including a Phase II candidate rescued from a struggling biotech.
